AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20950640 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard leaflet plus brief, tailored feedback based on pre-screening questionnaire
Number of subjects: 365
Study 20950640 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard leaflet on healthy lifestyle
Number of subjects: 365
Study 20950640 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 365
Study 17062840 — intervention group
Group type: EXPERIMENTAL
Intervention: LINS/SAL
Number of subjects: 9
Study 17062840 — intervention group
Group type: EXPERIMENTAL
Intervention: HINS/SAL
Number of subjects: 9
Study 17062840 — intervention group
Group type: EXPERIMENTAL
Intervention: LINS/HI
Number of subjects: 9
Study 17062840 — intervention group
Group type: EXPERIMENTAL
Intervention: HINS/HI
Number of subjects: 9
Study 17062840 — intervention group
Group type: EXPERIMENTAL
Intervention: HI
Number of subjects: 9
Study 16263089 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of delta-opioid receptors (DOR) and kappa-opioid receptors (KOR) in skin tissues
Number of subjects: 10
Study 16263089 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry, Western blot, and immunofluorescence techniques
Number of subjects: 10
Study 11867377 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine 2 mg IV
Number of subjects: 40
Study 11867377 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 40
Study 10714782 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial Bohler's angle measurement
Number of subjects: 88
Study 8846415 — intervention group
Group type: EXPERIMENTAL
Intervention: HOE‐140 (500 micrograms)
Number of subjects: 0
Study 8846415 — intervention group
Group type: EXPERIMENTAL
Intervention: HOE‐140 (5 min preadministration)
Number of subjects: 0
Study 8846415 — intervention group
Group type: EXPERIMENTAL
Intervention: HOE‐140 (2 h preadministration)
Number of subjects: 0
Study 8846415 — intervention group
Group type: EXPERIMENTAL
Intervention: HOE‐140
Number of subjects: 0
Study 1533186 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel (150 micrograms/day)
Number of subjects: 30
Study 1533186 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (150 micrograms/day)
Number of subjects: 30
Study 1533186 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic ethinyloestradiol plus levonorgestrel
Number of subjects: 30
Study 1533186 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyloestradiol plus desogestrel
Number of subjects: 30
Study 1533186 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphasic ethinyloestradiol plus levonorgestrel
Number of subjects: 30
Study 1533186 — intervention group
Group type: EXPERIMENTAL
Intervention: Both progestins (desogestrel and levonorgestrel)
Number of subjects: 30
Study 1533186 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of ethinyloestradiol to both progestins
Number of subjects: 30
Study 1533186 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 30
Study 1533186 — intervention group
Group type: EXPERIMENTAL
Intervention: All combinations with ethinyloestradiol
Number of subjects: 30
Study 1533186 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 30
Study 3904820 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 51
Study 3904820 — intervention group
Group type: COMPARATOR
Intervention: Adenine arabinoside
Number of subjects: 51
Study 3904820 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (excluding prior antiviral treatment)
Number of subjects: 51
Study 3904820 — intervention group
Group type: COMPARATOR
Intervention: Adenine arabinoside (excluding prior antiviral treatment)
Number of subjects: 51
Study 30466191 — intervention group
Group type: EXPERIMENTAL
Intervention: Mealtime fast-acting insulin aspart
Number of subjects: 606
Study 30466191 — intervention group
Group type: COMPARATOR
Intervention: Insulin aspart
Number of subjects: 606
Study 29127812 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline optimism
Number of subjects: 171
Study 26484622 — intervention group
Group type: EXPERIMENTAL
Intervention: Turquoise LED light
Number of subjects: 91
Study 26484622 — intervention group
Group type: COMPARATOR
Intervention: Blue LED light
Number of subjects: 91
Study 26636096 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Activation Measure (PAM) score with one missing item
Number of subjects: 1138
Study 26636096 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Activation Measure (PAM) score with twelve missing items
Number of subjects: 1138
Study 24111974 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam auto-injector (AI)
Number of subjects: 234
Study 24111974 — intervention group
Group type: COMPARATOR
Intervention: Placebo auto-injector (AI)
Number of subjects: 234
Study 20857087 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified inside-out transobturator procedure
Number of subjects: 175
Study 20857087 — intervention group
Group type: COMPARATOR
Intervention: Original inside-out transobturator procedure (TVT-O)
Number of subjects: 175
Study 18326962 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail education
Number of subjects: 380
Study 18326962 — intervention group
Group type: EXPERIMENTAL
Intervention: In-class education
Number of subjects: 380
Study 16793623 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg estradiol benzoate injected intramuscularly
Number of subjects: 112
Study 16793623 — intervention group
Group type: COMPARATOR
Intervention: Routine managements for uterine atony (control group)
Number of subjects: 112
Study 12657225 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (GH) administered for 3 months
Number of subjects: 16
Study 12657225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11080706 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) 400 microg administered twice daily
Number of subjects: 132
Study 11080706 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) 800 microg administered twice daily
Number of subjects: 132
Study 11080706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 9475305 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous jet-injection of recombinant human growth hormone (rhGH)
Number of subjects: 18
Study 9475305 — intervention group
Group type: COMPARATOR
Intervention: Conventional needle-injection of recombinant human growth hormone (rhGH)
Number of subjects: 18
Study 7714412 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin eyedrops (50 microliters of sterile normal saline containing varying insulin concentrations)
Number of subjects: 8
Study 7714412 — intervention group
Group type: COMPARATOR
Intervention: Placebo (50 microliters of sterile normal saline)
Number of subjects: 8
Study 7714412 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin eyedrops (100 U/ml in saline)
Number of subjects: 8
Study 7714412 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin eyedrops
Number of subjects: 8
Study 2455115 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg q.d. added to nifedipine 20 mg b.i.d.
Number of subjects: 14
Study 2455115 — intervention group
Group type: COMPARATOR
Intervention: Placebo q.d. added to nifedipine 20 mg b.i.d.
Number of subjects: 14
Study 27893474 — intervention group
Group type: EXPERIMENTAL
Intervention: Galileo (GAL) whole-body vibration with squat exercises (N = 15)
Number of subjects: 43
Study 27893474 — intervention group
Group type: EXPERIMENTAL
Intervention: Power-plate (POW) whole-body vibration with squat exercises (N = 14)
Number of subjects: 43
Study 27893474 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study 27893474 — intervention group
Group type: EXPERIMENTAL
Intervention: Galileo (GAL) whole-body vibration
Number of subjects: 43
Study 27893474 — intervention group
Group type: EXPERIMENTAL
Intervention: Power-plate (POW) whole-body vibration
Number of subjects: 43
Study 27893474 — intervention group
Group type: EXPERIMENTAL
Intervention: Galileo (GAL) and Power-plate (POW) groups
Number of subjects: 43
Study 27893474 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly squat exercises with whole-body vibration
Number of subjects: 43
Study 26994090 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam 1.5 g every 8 hours for 7 days
Number of subjects: 800
Study 26994090 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin 750 mg once daily for 7 days
Number of subjects: 800
Study 25450083 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic VSL#3 (9 × 10^11 bacteria) daily for 6 months
Number of subjects: 130
Study 25450083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 22956006 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg twice daily for 2 days)
Number of subjects: 94
Study 22956006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 22956006 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 94
Study 22956006 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone and Placebo
Number of subjects: 94
Study 20795923 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus inspiratory muscle training using a threshold device, with an initial load of 30% of their maximal inspiratory pressure, increased by 10% daily, administered for 5 min, twice a day, 7 days a week from the commencement of weaning until extubation.
Number of subjects: 41
Study 20795923 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 41
Study 20795923 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus inspiratory muscle training
Number of subjects: 41
Study 18773749 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatments (3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors, fibric acid derivatives, insulin sensitizers, cannabinoid receptor type 1 blockers)
Number of subjects: 0
Study 15657503 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone SPECT imaging
Number of subjects: 15
Study 15657503 — intervention group
Group type: COMPARATOR
Intervention: Supine SPECT imaging
Number of subjects: 15
Study 15657503 — intervention group
Group type: EXPERIMENTAL
Intervention: Both prone and supine imaging
Number of subjects: 15
Study 12233990 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation interventions (specifics not provided)
Number of subjects: 0
Study 12233990 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 8008680 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg daily)
Number of subjects: 31
Study 8008680 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (400 mg daily)
Number of subjects: 31
Study 8008680 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 31
Study 8008680 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol and Acebutolol therapy
Number of subjects: 31
Study 2514195 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF attempts in patients with unexplained infertility (UI)
Number of subjects: 143
Study 31586949 — intervention group
Group type: COMPARATOR
Intervention: One IVIg course
Number of subjects: 237
Study 31586949 — intervention group
Group type: EXPERIMENTAL
Intervention: Two IVIg courses (early)
Number of subjects: 237
Study 31586949 — intervention group
Group type: EXPERIMENTAL
Intervention: Two IVIg courses (late)
Number of subjects: 237
Study 31234948 — intervention group
Group type: EXPERIMENTAL
Intervention: Growing Together parenting education kit
Number of subjects: 1000
Study 31234948 — intervention group
Group type: COMPARATOR
Intervention: Standard care information resources
Number of subjects: 1000
Study 28685311 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal packing
Number of subjects: 72
Study 28685311 — intervention group
Group type: COMPARATOR
Intervention: Trans-septal suturing
Number of subjects: 72
Study 26037324 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred care approach (two-day initial training and ongoing support)
Number of subjects: 36
Study 26037324 — intervention group
Group type: COMPARATOR
Intervention: Optimised usual care (medication review by psychiatrist/geriatrician)
Number of subjects: 36
Study 26037324 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred care approach
Number of subjects: 36
Study 26037324 — intervention group
Group type: COMPARATOR
Intervention: Optimised usual care
Number of subjects: 36
Study 23814044 — intervention group
Group type: EXPERIMENTAL
Intervention: TCH (six cycles of docetaxel plus carboplatin combined with trastuzumab administered for 1 year)
Number of subjects: 3222
Study 23814044 — intervention group
Group type: COMPARATOR
Intervention: AC→TH (adjuvant doxorubicin and cyclophosphamide followed by docetaxel plus trastuzumab administered for 1 year)
Number of subjects: 3222
Study 23814044 — intervention group
Group type: COMPARATOR
Intervention: AC→T (four cycles of adjuvant doxorubicin and cyclophosphamide followed by four cycles of docetaxel)
Number of subjects: 3222
Study 23814044 — intervention group
Group type: EXPERIMENTAL
Intervention: TCH
Number of subjects: 3222
Study 21938372 — intervention group
Group type: EXPERIMENTAL
Intervention: Bryan cervical disc arthroplasty
Number of subjects: 181
Study 21938372 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion
Number of subjects: 181
Study 19249413 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 800
Study 19249413 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 800
Study 19249413 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Hydrochlorothiazide and Atenolol
Number of subjects: 800
Study 19249413 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific control mentioned)
Number of subjects: 800
Study 16805723 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin
Number of subjects: 0
Study 15090706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sauna therapy (60 degrees C far infrared-ray dry sauna for 15 minutes followed by bed rest with a blanket for 30 minutes once a day for two weeks)
Number of subjects: 28
Study 15090706 — intervention group
Group type: COMPARATOR
Intervention: Non-sauna group (control)
Number of subjects: 28
Study 11146706 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/d)
Number of subjects: 26
Study 11146706 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg twice daily)
Number of subjects: 26
Study 11146706 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of alendronate and naproxen
Number of subjects: 26
Study 9783096 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose ECT
Number of subjects: 40
Study 9783096 — intervention group
Group type: COMPARATOR
Intervention: Low dose ECT
Number of subjects: 40
Study 8193351 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine + 4-HC
Number of subjects: 15
Study 8193351 — intervention group
Group type: COMPARATOR
Intervention: 4-HC alone
Number of subjects: 15
Study 2555187 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg intravenously, followed by a continuous infusion of 10 mg.h-1)
Number of subjects: 10
Study 2555187 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study 2555187 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 10
Study 977997 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin plus cefazolin
Number of subjects: 10
Study 977997 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin alone
Number of subjects: 10
Study 31299212 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task (auditory cognitive task) during adaptation
Number of subjects: 28
Study 31299212 — intervention group
Group type: COMPARATOR
Intervention: Single-task during adaptation
Number of subjects: 28
Study 31299212 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task group during de-adaptation
Number of subjects: 28
Study 31299212 — intervention group
Group type: COMPARATOR
Intervention: Single-task group during de-adaptation
Number of subjects: 28
Study 27813398 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneously every 6 months
Number of subjects: 234
Study 27813398 — intervention group
Group type: COMPARATOR
Intervention: Alendronate 70 mg/week
Number of subjects: 234
Study 25352655 — intervention group
Group type: EXPERIMENTAL
Intervention: SAXA (5 mg/day) plus DAPA (10 mg/day) on background MET (≥1,500 mg/day)
Number of subjects: 534
Study 25352655 — intervention group
Group type: COMPARATOR
Intervention: SAXA (5 mg/day) plus MET
Number of subjects: 534
Study 25352655 — intervention group
Group type: COMPARATOR
Intervention: DAPA (10 mg/day) plus MET
Number of subjects: 534
Study 25352655 — intervention group
Group type: EXPERIMENTAL
Intervention: SAXA+DAPA+MET
Number of subjects: 534
Study 25352655 — intervention group
Group type: COMPARATOR
Intervention: SAXA+MET
Number of subjects: 534
Study 25352655 — intervention group
Group type: COMPARATOR
Intervention: DAPA+MET
Number of subjects: 534
Study 23530872 — intervention group
Group type: EXPERIMENTAL
Intervention: Resurfacing hip arthroplasty (RHA)
Number of subjects: 0
Study 23530872 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard total hip arthroplasty (THA)
Number of subjects: 0
Study 23530872 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-head total hip arthroplasty (THA)
Number of subjects: 0
Study 22926844 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrified-warmed oocytes with an intact corona radiata
Number of subjects: 6
Study 22926844 — intervention group
Group type: COMPARATOR
Intervention: Vitrified-warmed oocytes without a corona radiata
Number of subjects: 6
Study 22926844 — intervention group
Group type: COMPARATOR
Intervention: Fresh oocytes
Number of subjects: 6
Study 19669251 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE + thymalfasin (1.6 mg SC, 5 times weekly)
Number of subjects: 25
Study 19669251 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE + thymalfasin
Number of subjects: 25
Study 19669251 — intervention group
Group type: COMPARATOR
Intervention: TACE only
Number of subjects: 25
Study 17481705 — intervention group
Group type: EXPERIMENTAL
Intervention: High THBS-1
Number of subjects: 67
Study 17481705 — intervention group
Group type: EXPERIMENTAL
Intervention: bFGF
Number of subjects: 67
Study 17481705 — intervention group
Group type: EXPERIMENTAL
Intervention: THBS-1 after adjusting for prognostic factors
Number of subjects: 67
Study 17481705 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF and VEGFR-1
Number of subjects: 67
Study 14970093 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg twice daily orally for 3 days followed by placebo for 4 days (3-day group, 93 patients)
Number of subjects: 183
Study 14970093 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 250 mg twice daily orally for 7 days (7-day group, 90 patients)
Number of subjects: 183
Study 12243820 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (3 g in 15 mL suspension) administered rectally
Number of subjects: 86
Study 12243820 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same suspension without sucralfate) administered rectally
Number of subjects: 86
Study 12243820 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute RTOG/EORTC toxicity of Grade 2 or greater
Number of subjects: 86
Study 12243820 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal pain of moderate or severe grade during RT
Number of subjects: 86
Study 9678787 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil (600 mg b.d.)
Number of subjects: 29
Study 9678787 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate mono (400 mg daily)
Number of subjects: 29
Study 9678787 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 29
Study 7990255 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin sodium (IPM/CS)
Number of subjects: 171
Study 7990255 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin sodium plus amikacin sulfate (IPM/CS + AMK)
Number of subjects: 171
Study 2566637 — intervention group
Group type: EXPERIMENTAL
Intervention: Azidothymidine therapy
Number of subjects: 41
Study 31076415 — intervention group
Group type: EXPERIMENTAL
Intervention: Mealtime faster aspart
Number of subjects: 777
Study 31076415 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmeal faster aspart
Number of subjects: 777
Study 31076415 — intervention group
Group type: COMPARATOR
Intervention: Mealtime IAsp
Number of subjects: 777
Study 28656141 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT (High Intensity Training)
Number of subjects: 120
Study 28656141 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT&P (High Intensity Training with Protein Supplementation)
Number of subjects: 120
Study 28656141 — intervention group
Group type: EXPERIMENTAL
Intervention: HVHIT (High Volume/High-Intensity Training)
Number of subjects: 120
Study 28656141 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 120
Study 25588784 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dexamethasone (0.2 to 0.9 mg twice daily)
Number of subjects: 108
Study 25588784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 24014208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sesame lignans (50 mg, sesamin/episesamin=1/1)
Number of subjects: 48
Study 24014208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 21613040 — intervention group
Group type: COMPARATOR
Intervention: No autoclaving (0 cycles)
Number of subjects: 5
Study 21613040 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 autoclaving cycle
Number of subjects: 5
Study 21613040 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 autoclaving cycles
Number of subjects: 5
Study 21613040 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 autoclaving cycles
Number of subjects: 5
Study 21613040 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 autoclaving cycles
Number of subjects: 5
Study 19797261 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b (8 MIU)
Number of subjects: 73
Study 19797261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 16861412 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine + clonidine
Number of subjects: 3
Study 16861412 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine + fentanyl
Number of subjects: 3